Welcome!

News Feed Item

Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal

Study determines allografts with both amnion and chorion contain approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated

MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature. 

The Company's peer-reviewed article, "Cytokines in Single Layer Amnion/Chorion Allografts Compared to Multi-Layer Amnion/Chorion Allografts for Wound Healing," was electronically published in the Journal of Biomedical Materials Research Part B: Applied Biomaterials, on August 30, 2014. The paper was authored by Thomas J. Koob, PhD; Jeremy J. Lim, PhD; Nicole Zabek; and Michelle Massee. The electronic publication of the study in the Journal of Biomedical Materials Research is now available in the Wiley Online Library at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33265/pdf

The Company's previously published analyses have determined that over 50 growth factors, chemokines, cytokines, and regulatory factors are contained in PURION® Processed dehydrated human amnion/chorion membrane (dHACM) tissue allografts, specifically EpiFix®, a bilayer laminated graft containing both amnion and chorion. The scientific study was conducted to determine the relative contribution of each layer to the overall growth factor and cytokine content, as well as biological activity in the allograft. The study compared the results to the growth factor content in five representative commercially available single layer amnion grafts.

Study Highlights include:

  • MiMedx's multilayer amnion/chorion grafts (EpiFix® and AmnioFix®) contain approximately 20 times more growth factors and cytokines than the competitive single layer amnion grafts evaluated in the study.
  • AmbioDry2®, the MiMedx PURION® Processed single layer amnion, contains  four to five times greater amounts of growth factors than the competitive single layer amnion products (DryFlex®, AmnioExCel®, SteriShield™, and SteriShield II™) that were evaluated in the study.
  • EpiFix® contains four to five times the growth factors in AmbioDry2®.
  • All single layer amnion grafts that were tested contained substantially fewer growth factors and cytokines, and therefore, will deliver significantly less growth factors and cytokines than MiMedx's amnion/chorion multilayer grafts with the same surface area.
  • When calculated per surface area of tissue applied to a wound, the evaluated PURION® Processed amnion contained on average only 25% of the growth factor content contained in the PURION® Processed chorion.
  • The chorion layer in the MiMedx multi-layered allografts is four to five times thicker than the amnion layer, and therefore, contributes disproportionately to the growth factor content in amnion/chorion grafts. Chorion contributes on average 82% of the growth factors in EpiFix®.

"Recently, there has been misinformation in the market making the generalization that all amniotic membrane grafts are similar, regardless of whether they are single layer amnion or multi-layer allografts," said Parker H. Petit, Chairman and CEO.  "This study confirms that there is a substantial differentiation between multi-layer allografts with both amnion and chorion versus the single layer amnion allografts tested. This scientific study clearly demonstrates that PURION® Processed allografts with both amnion and chorion have a multiple of approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated in the study."

To examine the role of tissue processing technique in cytokine retention, cytokine contents in representative dehydrated single layer wound care products (DryFlex®, AmnioExCel®, SteriShield™ Single Layer, and SteriShield II™ Dual Layer) were measured. The results demonstrated that cytokine content varied significantly among the allografts tested, and that PURION® Processed single layer amnion grafts, AmbioDry2®, contained significantly more cytokines than the other single layer products that were evaluated in the study. "AmbioDry2® is the single layer wound care product MiMedx processes for its ophthalmic partner, IOP Ophthalmics, Inc. These results suggest that, as compared to other methods of tissue processing, the proprietary PURION® Processing contributes to greater cytokine retention and the delivery of substantially more growth factors, which are known to be critically important in wound repair and tissue regeneration," commented Bill Taylor, President and COO.

The publication suggests that the retention of biologically active growth factors during processing of amniotic tissues is critically important in preserving the bioactivity of the native tissues for wound care. "The abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds," stated Taylor.

The ability to induce fibroblast proliferation was studied, and it was determined that both the amnion and chorion caused dermal fibroblasts to proliferate. However, the chorion per square cm was on average five times more effective at inducing proliferation. "The study determined that the predominant basis for the bioactivity is derived from the chorion. This is a clear indication that the biological activity in EpiFix® that induces fibroblast proliferation is a result of both our proprietary processing technique and the graft's multi-layer configuration with both amnion and chorion," concluded Petit.

DryFlex®and AmnioExCel® are registered trademarks, and SteriShield™ and SteriShield II™ are trademarks of their respective owners. AmbioDry2® is private labeled for, and is a registered trademark of, IOP Ophthalmics, Inc.

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the importance of biologically active growth factors during processing of amniotic tissues in preserving the bioactivity of the native tissues for wound care and the contribution of the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts to these allografts' effectiveness in promoting the healing of refractive wounds.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the retention of biologically active growth factors during processing of amniotic tissues may prove not to be as important in preserving the bioactivity of the native tissues for wound care as the study suggests, that, in a head-to-head study,  the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may be found not to contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013.  By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We want to show that our solution is far less expensive with a much better total cost of ownership so we announced several key features. One is called geo-distributed erasure coding, another is support for KVM and we introduced a new capability called Multi-Part," explained Tim Desai, Senior Product Marketing Manager at Hitachi Data Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We provide IoT solutions. We provide the most compatible solutions for many applications. Our solutions are industry agnostic and also protocol agnostic," explained Richard Han, Head of Sales and Marketing and Engineering at Systena America, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
SYS-CON Events announced today that Calligo, an innovative cloud service provider offering mid-sized companies the highest levels of data privacy and security, has been named "Bronze Sponsor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Calligo offers unparalleled application performance guarantees, commercial flexibility and a personalised support service from its globally located cloud plat...
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.